Albendazole
Albendazole (albendazole) is a small molecule pharmaceutical. Albendazole was first approved as Albenza on 1996-06-11. It is used to treat ancylostomiasis, clonorchiasis, echinococcosis, enterobiasis, and giardiasis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Albendazole (discontinued: Albendazole, Albenza)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Albendazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALBENZA | Impax Laboratories | N-020666 DISCN | 1996-06-11 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| albendazole | ANDA | 2024-09-13 |
| albenza | New Drug Application | 2019-09-25 |
| anave skincare sunscreen | C200263 | 2024-07-26 |
| first aid beauty fab ultra repair skin protectant | C200263 | 2024-07-12 |
| it cosmetics your skin but better cc plus nude glow color correcting medium coverage skin tint plus brightening glow serum plus broad spectrum spf ... | C200263 | 2024-06-28 |
| mara clear skin mineral milk acne treatment | C200263 | 2024-06-13 |
| neutrogena | C200263 | 2024-07-17 |
| neutrogena oil-free acne wash sensitive skin facial cleanser fragrance free | C200263 | 2024-06-06 |
| pearlized antibacterial skin cleanser | C200263 | 2024-06-18 |
| proshield plus | C200263 | 2024-06-13 |
Show 9 more
Indications
FDA
EMA
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
143 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 7 | 4 | 7 | 15 | 32 |
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | 2 | 5 | 4 | 8 | 15 | 31 |
| Filariasis | D005368 | — | B74 | 1 | 6 | 5 | 4 | 12 | 27 |
| Filarial elephantiasis | D004605 | EFO_0007272 | B74.0 | 1 | 6 | 4 | 4 | 11 | 25 |
| Elephantiasis | D004604 | EFO_0004711 | — | 1 | 6 | 4 | 4 | 11 | 25 |
| Trichuriasis | D014257 | EFO_0007524 | — | — | 10 | 5 | 2 | 2 | 17 |
| Communicable diseases | D003141 | — | — | — | 2 | 1 | 4 | 8 | 15 |
| Hookworm infections | D006725 | EFO_0007314 | B76 | — | 6 | 3 | 1 | 4 | 13 |
| Ancylostomiasis | D000724 | EFO_0007145 | B76.0 | — | 6 | 3 | 1 | 3 | 12 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | 2 | 1 | 8 | 11 |
Show 25 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 3 | — | 6 | 9 |
| Onchocerciasis | D009855 | EFO_0007402 | B73 | — | 3 | 3 | — | 3 | 9 |
| Strongyloidiasis | D013322 | EFO_0007501 | B78 | — | — | 2 | — | 2 | 4 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 1 | — | 2 | 3 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | 1 | — | — | 3 |
| Yaws | D015001 | EFO_0007548 | A66 | — | 1 | 1 | — | — | 2 |
| Scabies | D012532 | — | B86 | — | — | 1 | — | 1 | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | — | 1 | 2 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | 1 | — | 1 | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 1 | — | 1 | 2 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wuchereria bancrofti | D014958 | — | — | 1 | 1 | — | — | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Typhoid fever | D014435 | EFO_0006789 | A01.0 | 1 | 1 | — | — | — | 1 |
| Cholera | D002771 | — | A00 | 1 | 1 | — | — | — | 1 |
| Intestinal volvulus | D045822 | EFO_1000989 | K56.2 | — | 1 | — | — | — | 1 |
| Ocular onchocerciasis | D015827 | EFO_0007398 | B73 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Combination drug therapy | D004359 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| African trypanosomiasis | D014353 | — | B56 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coinfection | D060085 | — | — | — | — | — | — | 4 | 4 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | — | — | — | 2 | 2 |
| Echinococcosis | D004443 | EFO_0007245 | B67 | — | — | — | — | 2 | 2 |
| Growth disorders | D006130 | — | — | — | — | — | — | 1 | 1 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
| Impetigo | D007169 | EFO_1000714 | L01 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Show 36 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Albendazole |
| INN | albendazole |
| Description | Albendazole is a carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations. It has a role as a tubulin modulator, a microtubule-destabilising agent and an anthelminthic drug. It is a carbamate ester, a benzimidazolylcarbamate fungicide, an aryl sulfide and a member of benzimidazoles. |
| Classification | Small molecule |
| Drug class | antithelmintics (tibendazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 54965-21-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1483 |
| ChEBI ID | 16664 |
| PubChem CID | 2082 |
| DrugBank | DB00518 |
| UNII ID | F4216019LN (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Albendazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,235 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,522 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use